増殖糖尿病網膜症（PDR）の世界市場レポート 2025年

増殖糖尿病網膜症（PDR）市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.5％で40億2,000万米ドルに成長します。予測期間の成長は、人口の高齢化、糖尿病に関する一般市民の認識と教育、研究開発資金、併用療法に対する需要の高まりに起因すると考えられます。予測期間における主な動向には、診断技術の進歩、治療オプションの革新、早期診断のための人工知能（AI）、遺伝子治療の進歩、高度な網膜イメージングなどがあります。

糖尿病の有病率の増加が増殖糖尿病網膜症（PDR）市場の成長を促進すると予測されます。糖尿病は、血糖値の上昇を特徴とする慢性疾患であり、増殖性糖尿病網膜症の主な原因であるが、網膜のさらなる損傷を防ぎ、視力の維持を助ける治療で管理することができます。例えば、2024年6月の英国国民保健サービス（NHS）のデータでは、40歳未満の糖尿病患者が2022年の173,166人から2023年には216,440人に増加しています。この顕著な増加は、若年層における懸念すべき傾向を強調しています。その結果、糖尿病有病率の上昇はPDR市場を前進させる重要な要因となっています。

肥満の有病率の増加は、増殖糖尿病網膜症（PDR）市場の今後の成長にとって重要な促進要因になると予想されます。肥満は、さまざまな要因を持つ多面的な慢性疾患であり、体脂肪の過剰蓄積と潜在的な健康問題をもたらします。肥満は、インスリン抵抗性、慢性的な低級炎症、酸化ストレスの高まりと密接に関連しており、これらすべてが網膜微小血管系に悪影響を及ぼし、糖尿病網膜症の発症の一因となる可能性があります。例えば、米国の非営利団体Trust for America's Healthが2022年に発表した報告書によると、米国の肥満率は上昇傾向にあり、米国成人の10人に4人が肥満の影響を受けています。これは前年に比べ増加したことを示しており、成人の肥満率が35％を超えたと報告した州は19州と、前年の16州から増加しています。その結果、肥満の深刻化は増殖糖尿病網膜症（PDR）市場の拡大を促進する極めて重要な触媒となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界増殖糖尿病網膜症（PDR） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の増殖糖尿病網膜症（PDR）市場：成長率分析
• 世界の増殖糖尿病網膜症（PDR）市場の実績：規模と成長, 2019-2024
• 世界の増殖糖尿病網膜症（PDR）市場の予測：規模と成長, 2024-2029, 2034F
• 世界増殖糖尿病網膜症（PDR）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の増殖糖尿病網膜症（PDR）市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗VEGF（血管内皮増殖因子）療法
• 眼内ステロイド
• レーザー手術
• 硝子体切除術
• 世界の増殖糖尿病網膜症（PDR）市場投与方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射剤
• オーラル
• その他の管理方法
• 世界の増殖糖尿病網膜症（PDR）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他の用途
• 世界の増殖糖尿病網膜症（PDR）市場抗VEGF療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アフリベルセプト
• ラニビズマブ
• ベバシズマブ
• 世界の増殖糖尿病網膜症（PDR）市場眼内ステロイドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリアムシノロンアセトニド
• デキサメタゾンインプラント
• フルオシノロンアセトニド
• 世界の増殖糖尿病網膜症（PDR）市場、レーザー手術の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 焦点レーザー光凝固術
• 汎網膜レーザー光凝固術
• 世界の増殖糖尿病網膜症（PDR）市場硝子体切除術のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 硝子体切除術
• 前部硝子体切除術

第7章 地域別・国別分析

• 世界の増殖糖尿病網膜症（PDR）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の増殖糖尿病網膜症（PDR）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 増殖糖尿病網膜症（PDR）市場：競合情勢
• 増殖糖尿病網膜症（PDR）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GSK plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Merck KGaA
• Kubota Vision Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 増殖糖尿病網膜症（PDR）市場2029：新たな機会を提供する国
• 増殖糖尿病網膜症（PDR）市場2029：新たな機会を提供するセグメント
• 増殖糖尿病網膜症（PDR）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Proliferative diabetic retinopathy (PDR) represents an advanced stage of diabetic eye disease marked by the development of abnormal blood vessels in the retina. This occurrence is primarily attributed to prolonged high levels of blood sugar. If left unaddressed, these abnormal vessels can result in retinal bleeding, scarring, and impaired vision. Consequently, regular eye examinations are of paramount importance for early detection and effective management.

The primary treatment options for proliferative diabetic retinopathy encompass anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery, and vitrectomy. Intraocular steroids involve the direct administration of medications into the eye, which serves to address inflammation and manage conditions like diabetic macular edema or uveitis. This approach aids in reducing swelling and enhancing visual outcomes. Various modes of administration, including injectables, oral medications, and others, find application in settings such as hospitals, clinics, and more.

The proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides proliferative diabetic retinopathy market statistics, including proliferative diabetic retinopathy industry global market size, regional shares, competitors with a proliferative diabetic retinopathy market share, detailed proliferative diabetic retinopathy market segments, market trends and opportunities and any further data you may need to thrive in the proliferative diabetic retinopathy industry. This proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proliferative diabetic retinopathy (PDR) market size has grown rapidly in recent years. It will grow from $2.42 billion in 2024 to $2.7 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.

The proliferative diabetic retinopathy (PDR) market size is expected to see rapid growth in the next few years. It will grow to $4.02 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (AI) for early diagnosis, gene therapy advancements, advanced retinal imaging.

The increasing prevalence of diabetes is anticipated to drive growth in the proliferative diabetic retinopathy (PDR) market. Diabetes, a chronic condition marked by elevated blood glucose levels, is the primary cause of proliferative diabetic retinopathy, which can be managed with treatments that prevent further retinal damage and help preserve vision. For example, in June 2024, data from the UK's National Health Service (NHS) showed a rise in diabetes cases among individuals under 40, from 173,166 in 2022 to 216,440 in 2023. This notable increase underscores a concerning trend in younger populations. Consequently, the rising diabetes prevalence is a key factor driving the PDR market forward.

The increasing prevalence of obesity is expected to be a key driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Obesity, a multifaceted, chronic condition with various contributing factors, results in an excess accumulation of body fat and potential health issues. Obesity is closely associated with insulin resistance, chronic low-grade inflammation, and heightened oxidative stress, all of which can adversely affect the retinal microvasculature and contribute to the onset of diabetic retinopathy. For instance, according to a 2022 report released by Trust for America's Health, a non-profit organization in the United States, obesity rates in the country are on the rise, with four out of every ten American adults being affected by obesity. This represents an increase compared to the previous year, with 19 states reporting adult obesity rates exceeding 35%, up from 16 states in the preceding year. Consequently, the escalating prevalence of obesity serves as a pivotal catalyst driving the expansion of the proliferative diabetic retinopathy (PDR) market.

Prominent companies operating in the proliferative diabetic retinopathy market maintain a consistent focus on the development of groundbreaking therapies. This strategic emphasis aims to enhance treatment efficacy, alleviate the treatment-related financial burden, and ultimately elevate patient outcomes. For instance, in June 2022, Biogen, a leading US-based biotechnology company, partnered with Samsung Bioepis, a South Korea-based biotech company, to introduce Byooviz (ranibizumab-nuna). Byooviz represents the first ophthalmology biosimilar in the United States, offering treatment options for patients dealing with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization. These innovative therapies are poised to bring transformative changes to the landscape of proliferative diabetic retinopathy treatment.

In July 2024, Merck & Co., Inc., a U.S.-based healthcare company specializing in medicines, vaccines, and animal health products, acquired Eyebiotech Limited for $3 billion. Through this acquisition, Merck aims to strengthen its ophthalmology pipeline by advancing innovative treatments for sight-threatening retinal diseases and addressing critical unmet needs in this field. Eyebiotech Limited, a UK-based biotechnology company, focuses on developing therapies for proliferative diabetic retinopathy to counteract abnormal retinal blood vessel growth.

Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the proliferative diabetic retinopathy (PDR) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The proliferative diabetic retinopathy (PDR) market consists of sales of laser therapy, systemic therapies and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The proliferative diabetic retinopathy (PDR) market also includes sales of corticosteroids, ranibizumab, bevacizumab and fluocinolone acetonide drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Proliferative Diabetic Retinopathy (PDR) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on proliferative diabetic retinopathy (pdr) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for proliferative diabetic retinopathy (pdr) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The proliferative diabetic retinopathy (pdr) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy; Intraocular Steroids; Laser Surgery; Vitrectomy
• 2) By Mode of Administration: Injectables; Oral; Other Mode Of Administrations
• 3) By Application: Hospitals; Clinics; Other Applications
• Subsegments:
• 1) By Anti-VEGF Therapy: Aflibercept; Ranibizumab; Bevacizumab
• 2) By Intraocular Steroids: Triamcinolone Acetonide; Dexamethasone Implant; Fluocinolone Acetonide
• 3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Laser Photocoagulation
• 4) By Vitrectomy: Pars Plana Vitrectomy; Anterior Vitrectomy
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; F. Hoffmann-La Roche Ltd.; Merck and Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Proliferative Diabetic Retinopathy (PDR) Market Characteristics

3. Proliferative Diabetic Retinopathy (PDR) Market Trends And Strategies

4. Proliferative Diabetic Retinopathy (PDR) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Proliferative Diabetic Retinopathy (PDR) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Proliferative Diabetic Retinopathy (PDR) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Proliferative Diabetic Retinopathy (PDR) Market Growth Rate Analysis
• 5.4. Global Proliferative Diabetic Retinopathy (PDR) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Proliferative Diabetic Retinopathy (PDR) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Proliferative Diabetic Retinopathy (PDR) Total Addressable Market (TAM)

6. Proliferative Diabetic Retinopathy (PDR) Market Segmentation

• 6.1. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-VEGF (Vascular Endothelial Growth Factor) Therapy
• Intraocular Steroids
• Laser Surgery
• Vitrectomy
• 6.2. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Oral
• Other Mode Of Administrations
• 6.3. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other Applications
• 6.4. Global Proliferative Diabetic Retinopathy (PDR) Market, Sub-Segmentation Of Anti-VEGF Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aflibercept
• Ranibizumab
• Bevacizumab
• 6.5. Global Proliferative Diabetic Retinopathy (PDR) Market, Sub-Segmentation Of Intraocular Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triamcinolone Acetonide
• Dexamethasone Implant
• Fluocinolone Acetonide
• 6.6. Global Proliferative Diabetic Retinopathy (PDR) Market, Sub-Segmentation Of Laser Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Focal Laser Photocoagulation
• Panretinal Laser Photocoagulation
• 6.7. Global Proliferative Diabetic Retinopathy (PDR) Market, Sub-Segmentation Of Vitrectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pars Plana Vitrectomy
• Anterior Vitrectomy

7. Proliferative Diabetic Retinopathy (PDR) Market Regional And Country Analysis

• 7.1. Global Proliferative Diabetic Retinopathy (PDR) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Proliferative Diabetic Retinopathy (PDR) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market

• 8.1. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Proliferative Diabetic Retinopathy (PDR) Market

• 9.1. China Proliferative Diabetic Retinopathy (PDR) Market Overview
• 9.2. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Proliferative Diabetic Retinopathy (PDR) Market

• 10.1. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Proliferative Diabetic Retinopathy (PDR) Market

• 11.1. Japan Proliferative Diabetic Retinopathy (PDR) Market Overview
• 11.2. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Proliferative Diabetic Retinopathy (PDR) Market

• 12.1. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Proliferative Diabetic Retinopathy (PDR) Market

• 13.1. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Proliferative Diabetic Retinopathy (PDR) Market

• 14.1. South Korea Proliferative Diabetic Retinopathy (PDR) Market Overview
• 14.2. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Proliferative Diabetic Retinopathy (PDR) Market

• 15.1. Western Europe Proliferative Diabetic Retinopathy (PDR) Market Overview
• 15.2. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Proliferative Diabetic Retinopathy (PDR) Market

• 16.1. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Proliferative Diabetic Retinopathy (PDR) Market

• 17.1. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Proliferative Diabetic Retinopathy (PDR) Market

• 18.1. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Proliferative Diabetic Retinopathy (PDR) Market

• 19.1. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Proliferative Diabetic Retinopathy (PDR) Market

• 20.1. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market

• 21.1. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market Overview
• 21.2. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Proliferative Diabetic Retinopathy (PDR) Market

• 22.1. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Proliferative Diabetic Retinopathy (PDR) Market

• 23.1. North America Proliferative Diabetic Retinopathy (PDR) Market Overview
• 23.2. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Proliferative Diabetic Retinopathy (PDR) Market

• 24.1. USA Proliferative Diabetic Retinopathy (PDR) Market Overview
• 24.2. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Proliferative Diabetic Retinopathy (PDR) Market

• 25.1. Canada Proliferative Diabetic Retinopathy (PDR) Market Overview
• 25.2. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Proliferative Diabetic Retinopathy (PDR) Market

• 26.1. South America Proliferative Diabetic Retinopathy (PDR) Market Overview
• 26.2. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Proliferative Diabetic Retinopathy (PDR) Market

• 27.1. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Proliferative Diabetic Retinopathy (PDR) Market

• 28.1. Middle East Proliferative Diabetic Retinopathy (PDR) Market Overview
• 28.2. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Proliferative Diabetic Retinopathy (PDR) Market

• 29.1. Africa Proliferative Diabetic Retinopathy (PDR) Market Overview
• 29.2. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Proliferative Diabetic Retinopathy (PDR) Market Competitive Landscape And Company Profiles

• 30.1. Proliferative Diabetic Retinopathy (PDR) Market Competitive Landscape
• 30.2. Proliferative Diabetic Retinopathy (PDR) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Proliferative Diabetic Retinopathy (PDR) Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. AstraZeneca plc
• 31.6. GSK plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Amgen Inc.
• 31.10. Novo Nordisk A/S
• 31.11. Boehringer Ingelheim International GmbH
• 31.12. Merck KGaA
• 31.13. Kubota Vision Inc.
• 31.14. Teva Pharmaceutical Industries Ltd.
• 31.15. Regeneron Pharmaceuticals Inc.

32. Global Proliferative Diabetic Retinopathy (PDR) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Proliferative Diabetic Retinopathy (PDR) Market

34. Recent Developments In The Proliferative Diabetic Retinopathy (PDR) Market

35. Proliferative Diabetic Retinopathy (PDR) Market High Potential Countries, Segments and Strategies

• 35.1 Proliferative Diabetic Retinopathy (PDR) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Proliferative Diabetic Retinopathy (PDR) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Proliferative Diabetic Retinopathy (PDR) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer